{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-280518","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.184228+00:00","generated_at":"2026-05-16T20:27:56.065239+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spero Therapeutics Q3 net loss narrows to $7.4M; GSK plans FDA filing for tebipenem HBr in Q4 2025","bullets":["Net loss of $7.4M ($0.13 EPS) vs $17.1M ($0.32 EPS) in Q3 2024; revenue $5.4M, down from $13.5M.","Cash and equivalents $48.6M as of Sep 30, 2025; company expects funding into 2028.","Phase 3 PIVOT-PO trial of tebipenem HBr met primary endpoint; GSK to submit NDA to FDA in Q4 2025 with decision expected 2H 2026.","SPR720 program for NTM pulmonary disease discontinued in Q3 2025 after Phase 2a/1 data review.","R&D expenses fell to $8.6M from $26.9M due to lower PIVOT-PO and SPR720 costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-280518","json":"https://secwatch.observer/filing/0001193125-25-280518.json","markdown":"https://secwatch.observer/filing/0001193125-25-280518.md","text":"https://secwatch.observer/filing/0001193125-25-280518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525280518/0001193125-25-280518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525280518/d44321d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:27:56.065239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}